Skip to main content

Table 1 Complement activation in plasma from patients with Crohn's disease (CD), patients with ulcerative colitis (UC) and healthy subjects (HS) before and after 1, 6 and 12 weeks high-dose treatment with prednisolone.

From: Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis

 

before treatment

after 1 week

after 6 weeks

after 12 weeks

 

Number of patients

Number of patients

Number of patients

Number of patients

CD

18

18

18

18

UC

18

18

18

16

HS

38

--

--

--

C3-AC, alternative

% of standard

% of standard

% of standard

% of standard

CD

61.5 (53–82)

51.5 (49–71)

55.5 (49–70)

59 (49–75)

UC

58 (49–78)

49 (49–70)

49 (49–78)

59 (49–70)

HS

49 (49–67)

--

--

--

C3-AC, classical

% of standard

% of standard

% of standard

% of standard

CD

109 (81–172)

97.5 (39–124)

94.5 (70–141)

99.5 (53–143)

UC

97 (39–148)

88 (58–129)

91 (59–115)

94 (39–160)

HS

82.5 (68–108)

--

--

--

MBL-concentration

ng/ml

ng/ml

ng/ml

ng/ml

CD

3251 (14 – 6085)

3071 (10 – 4636)

2911 (10 – 5178)

3257 (10 – 4718)

UC

1082 (6 – 3926)

1171 (3 – 4845)

1141 (3 – 4590)

1292 (3 – 4147)

HS

1219 (2 – 3577)

--

--

--

MBL-C4-AC

% of standard

% of standard

% of standard

% of standard

CD

118 (21–187)

63 (25–192)

62.5 (21–163)

87 (17–192)

UC

54 (12–201)

54 (11–192)

45 (9–163)

55 (12–192)

HS

66.5 (9–162)

--

--

--

  1. Median and range (in parenthesis) of alternative and classical pathway-mediated C3-activation capacity(C3-AC), mannan-binding lectin (MBL) concentration, MBL-C4-AC.